<DOC>
	<DOC>NCT02140372</DOC>
	<brief_summary>This is a pilot study. Volunteers will be given 1.8 mg (1.2 mg followed by 0.6 mg one hour later), 1.2 mg, or 0.6 mg of colchicine. Blood will be collected prior to drug administration, 2 hours after colchicine administration, and 24 hours after colchicine administration via the antecubital vein and evaluated for markers of platelet activity and inflammation.</brief_summary>
	<brief_title>Anti-platelet Effects of Colchicine in Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Colchicine</mesh_term>
	<criteria>Subjects must be more than 18 years of age 1) history of cardiovascular disease, including myocardial infarction, history of percutaneous coronary angioplasty or stent, peripheral vascular disease or stroke; 2) history of myelodysplasia; 3) medications known to affect platelet function, including nonsteroidal antiinflammatory drugs, antihistamines, and selective serotonin reuptake inhibitors, during the 5 days prior to participation; 4) medications known to interact with colchicine; 5) history of intolerance to colchicine; 6) acute or chronic symptoms of diarrhea, nausea, or vomiting within 1 month prior to enrollment; 7) known anemia or hemoglobin &lt;10mg/dL; 8) platelet count &lt;100,000 or &gt; 450,000; 9) creatinine clearance &lt;30cc/minute; 10) any known hemorrhagic diathesis; 11) pregnant; 12) Unable to consent; or 13) Participating in a competing study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>colchicine</keyword>
	<keyword>platelet activity</keyword>
	<keyword>neutrophil</keyword>
</DOC>